Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
Clinical trial NCT05430802 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05430802
- Sponsor
- Tang-Du Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-24
- Primary completion
- 2025-09-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.